SciClone Pays $20 Million to AbilityPharma for China Rights to Cancer Drug

SciClone, a US pharma focused on the China market, in-licensed China rights to a solid tumor cancer drug from Spain's AbilityPharma in a deal potentially worth $20 million. ABTL0812 has completed a Phase I/Ib trial in Spain. In exchange for greater China rights to the drug, SciClone will make an upfront payment along with development, regulatory and sales milestones plus royalties. In Europe and the US, ABTL081 was given Organ Drug status for pediatric cancer neuroblastoma. More details.... Stock Symbol: (NSDQ: SCLN) Share this with colleagues: // //